Axon (AXON) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In the latest trading session, Axon Enterprise (AXON) closed at $424.69, marking a +2.32% move from the previous day.
In the latest trading session, Axon Enterprise (AXON) closed at $415.07, marking a -3.46% move from the previous day.
Axon (AXON) reported earnings 30 days ago. What's next for the stock?
Axon Enterprise posts 36% EBITDA growth with margin expansion, but rising costs test sustainability as it targets steady margins in 2026.
In the most recent trading session, Axon Enterprise (AXON) closed at $507.28, indicating a +2.22% shift from the previous trading day.
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
AXON's Software & Services revenues jump nearly 40% in 2025 as rising subscriptions and recurring revenues drive a strong growth outlook.
Axon (AXON) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Axon Enterprise (AXON) – a supplier of TASER devices and digital evidence solutions for law enforcement – has experienced a 6-day losing streak, with total losses during this timeframe reaching -15%. The company's market capitalization has plummeted by approximately $6.7 billion over the past 6 days, and it currently amounts to $39 billion.
Astronics (OTCMKTS:ATROB - Get Free Report) and Axon Enterprise (NASDAQ: AXON - Get Free Report) are both aerospace companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations. Analyst Ratings This is a breakdown of current ratings
Capital International Investors reduced its stake in Axon Enterprise, Inc (NASDAQ: AXON) by 22.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 58,669 shares of the biotechnology company's stock after selling 17,091 shares during the quarter. Capital International Investors owned approximately